Milestone Pharmaceuticals: Early Launch Metrics Show Breadth, But Revenue Inflection Still Unproven

What happened

Milestone Pharmaceuticals (MIST) shares have fallen 37% since FDA approval of Cardamyst, reflecting market skepticism about commercial execution. The DeepValue Master Report rates MIST a WAIT at $1.70, citing only 25% commercial lives covered, scripts nearly equal to patients (no refills), and $16.1M quarterly cash burn. A bullish Seeking Alpha article argues that rapid-acting efficacy, expanding insurance coverage, and a unique market position will drive a revenue ramp. However, filings show Q1’26 net revenue of just $0.238M against a $26.1M net loss, and the royalty financing carries a 19.6% effective interest rate. The stock price currently reflects an approved product but not yet a proven reimbursement-to-refill engine.

Implication

The next 2-3 quarters are critical: if CARDAMYST's coverage exceeds 50% of commercial lives and scripts per patient rise above 1.3x, the stock could re-rate to $2.40+. Conversely, failure to expand coverage or demonstrate repeat utilization will likely lead to dilution risk and downside toward $1.10. The AFib-RVR Phase 3 enrollment is an optionality driver but secondary to near-term launch metrics.

Thesis delta

The bullish Seeking Alpha narrative assumes a revenue ramp is imminent, but the DeepValue analysis shows that early launch KPIs do not yet confirm a self-sustaining commercial trajectory. Our thesis shifts from 'wait for launch traction' to 'require two observable metrics: coverage >50% and scripts/patient >1.3x' before underwriting upside. The recent stock decline is not a buying opportunity until these metrics inflect.